Tags

Type your tag names separated by a space and hit enter

Escitalopram in the acute treatment of depressed patients aged 60 years or older.
Am J Geriatr Psychiatry. 2008 Jan; 16(1):14-20.AJ

Abstract

OBJECTIVE

The present study examined the efficacy and tolerability of acute escitalopram treatment in depressed patients aged 60 years or older.

METHODS

Patients aged > or =60 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition major depressive disorder were randomized to 12 weeks of double-blind, flexible-dose treatment with escitalopram (10-20 mg/day; N = 130) or placebo (N = 134). The prospectively defined primary efficacy end point was change from baseline to week 12 in Montgomery-Asberg Depression Rating Scale (MADRS) total score using the last observation carried forward approach.

RESULTS

A total of 109 (81%) patients in the placebo group and 96 (74%) patients in the escitalopram group completed treatment. Mean age in both groups was approximately 68 years. Mean baseline MADRS scores were 28.4 and 29.4 for the placebo and escitalopram treatment groups, respectively. Escitalopram did not achieve statistical significance compared with placebo in change from baseline on the MADRS (least square mean difference: -1.34; last observation carried forward). Discontinuation rates resulting from adverse events were 6% for placebo and 11% for escitalopram. Treatment-emergent adverse events reported by >10% of patients in the escitalopram group were headache, nausea, diarrhea, and dry mouth.

CONCLUSIONS

Escitalopram treatment was not significantly different from placebo treatment on the primary efficacy measure, change from baseline to week 12 in MADRS. In patients aged 60 years or older with major depression, acute escitalopram treatment appeared to be well tolerated.

Authors+Show Affiliations

Forest Research Institute, Harborside Financial Center, Jersey City, NJ 07311, USA. anjana.bose@frx.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18165459

Citation

Bose, Anjana, et al. "Escitalopram in the Acute Treatment of Depressed Patients Aged 60 Years or Older." The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry, vol. 16, no. 1, 2008, pp. 14-20.
Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry. 2008;16(1):14-20.
Bose, A., Li, D., & Gandhi, C. (2008). Escitalopram in the acute treatment of depressed patients aged 60 years or older. The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry, 16(1), 14-20. https://doi.org/10.1097/JGP.0b013e3181591c09
Bose A, Li D, Gandhi C. Escitalopram in the Acute Treatment of Depressed Patients Aged 60 Years or Older. Am J Geriatr Psychiatry. 2008;16(1):14-20. PubMed PMID: 18165459.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Escitalopram in the acute treatment of depressed patients aged 60 years or older. AU - Bose,Anjana, AU - Li,Dayong, AU - Gandhi,Chetan, PY - 2008/1/1/pubmed PY - 2008/2/29/medline PY - 2008/1/1/entrez SP - 14 EP - 20 JF - The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry JO - Am J Geriatr Psychiatry VL - 16 IS - 1 N2 - OBJECTIVE: The present study examined the efficacy and tolerability of acute escitalopram treatment in depressed patients aged 60 years or older. METHODS: Patients aged > or =60 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition major depressive disorder were randomized to 12 weeks of double-blind, flexible-dose treatment with escitalopram (10-20 mg/day; N = 130) or placebo (N = 134). The prospectively defined primary efficacy end point was change from baseline to week 12 in Montgomery-Asberg Depression Rating Scale (MADRS) total score using the last observation carried forward approach. RESULTS: A total of 109 (81%) patients in the placebo group and 96 (74%) patients in the escitalopram group completed treatment. Mean age in both groups was approximately 68 years. Mean baseline MADRS scores were 28.4 and 29.4 for the placebo and escitalopram treatment groups, respectively. Escitalopram did not achieve statistical significance compared with placebo in change from baseline on the MADRS (least square mean difference: -1.34; last observation carried forward). Discontinuation rates resulting from adverse events were 6% for placebo and 11% for escitalopram. Treatment-emergent adverse events reported by >10% of patients in the escitalopram group were headache, nausea, diarrhea, and dry mouth. CONCLUSIONS: Escitalopram treatment was not significantly different from placebo treatment on the primary efficacy measure, change from baseline to week 12 in MADRS. In patients aged 60 years or older with major depression, acute escitalopram treatment appeared to be well tolerated. SN - 1064-7481 UR - https://www.unboundmedicine.com/medline/citation/18165459/Escitalopram_in_the_acute_treatment_of_depressed_patients_aged_60_years_or_older_ L2 - https://linkinghub.elsevier.com/retrieve/pii/16/1/14 DB - PRIME DP - Unbound Medicine ER -